| Literature DB >> 11443559 |
J F Kun1, B Mordmüller, D J Perkins, J May, O Mercereau-Puijalon, M Alpers, J B Weinberg, P G Kremsner.
Abstract
A point mutation in the promoter of the nitric oxide synthase 2 gene (NOS2), termed NOS2(Lambaréné) (NOS2-G954C), protects heterozygous carriers against severe malaria as effectively as the sickle cell trait. In a prospective longitudinal study, 841 individual infections of initially 200 children (151 wild-type vs. 49 NOS2(Lambaréné) carriers) were monitored for 4 years, to assess the rates of malarial attacks in the 2 groups; carriers of the NOS2(Lambaréné) polymorphism were significantly less likely to experience malarial attacks than were others (P=.002). The distribution of the NOS2(Lambaréné) polymorphism was investigated in malaria-endemic areas. It was found to be present with the highest frequency in Africa and at a lower frequency in Asia. Ex vivo studies showed that cells isolated from people with this polymorphism have a 7-fold higher baseline NOS activity, compared with the levels detected in cells from subjects with the wild-type gene (P=.003).Entities:
Mesh:
Substances:
Year: 2001 PMID: 11443559 DOI: 10.1086/322037
Source DB: PubMed Journal: J Infect Dis ISSN: 0022-1899 Impact factor: 5.226